Answers are grounded in this paper and cite their sources.
Background To investigate the changes of human leukocyte antigen DR (HLA-DR) and CD38 coexpression subsets on T lymphocytes following interferon (IFN) therapy for those who have chronic hepatitis B (CHB). Methods A prospective cohort of CHB patients participated in this study. CHB patients without IFN treatment (including naïve and nucleoside [nucleotide] analogs [NAs]-treated patients) were given pegylated interferon alfa (Peg-IFNα) treatment. Peripheral blood samples were taken at baseline, 4 weeks and 12-24 weeks of Peg-IFNα treatment. For the patients who entered the Peg-IFNα plateau phase due to the stagnation of the decrease in HBsAg, and Peg-IFNα was discontinued and Peg-IFNα therapy was resumed after an interval of 12-24 weeks. During the interval, they received first-line NAs treatment. Peripheral blood samples were collected at the baseline of the plateau phase, 12-24 weeks of intermittent treatment, and 12-24 weeks of Peg-IFNα retreatment. The peripheral blood samples were taken to determine virological, serological and biochemical indices of hepatitis B virus (HBV), and T lymphocyte related phenotypes were detected using flow cytometry. Results In the process of long-term treatment of Peg-IFNα, the percentage of HLA-DR + CD38 dim subsets increased significantly at first, then decreased gradually, while the percentage of HLA-DR + CD38 hi subsets markedly increased. During long-term Peg-IFNα treatment, there was a considerable negative correlation between HBsAg and the HLA-DR + CD38 hi subset percentage. The persistent high proportion of HLA-DR + CD38 hi subsets was related to the occurrence of Peg-IFNα plateau phase. After Peg-IFNα intermittent treatment, the percentage of HLA-DR + CD38 hi subsets decreased significantly. After Peg-IFNα retreatment, the level of HBsAg began to decrease again. At the same time, the percentage of HLA-DR + CD38 hi subsets significantly increased, but it was still lower than that at the baseline level. Conclusions The spectrum of HLA-DR and CD38 coexpression subsets on T lymphocytes changed during the long-term treatment of IFN. The establishment of the IFN plateau phase was linked to the persistence of a considerable proportion of HLA-DR + CD38 hi subsets on T lymphocytes. IFN intermittent treatment could significantly reduce the proportion of HLA-DR + CD38 hi subsets, helping regain the antiviral efficacy of IFN during IFN retreatment.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: